The nucleus basalis of Meynert: A new target for deep brain stimulation in dementia?

Neuroscience and Biobehavioral Reviews

Volumn 37, Issue 10, 2013, Pages 2676-2688

  Gratwicke, James ^a   Kahan, Joshua ^a   Zrinzo, Ludvic ^a   Hariz, Marwan ^a   Limousin, Patricia ^a   Foltynie, Thomas ^a   Jahanshahi, Marjan ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Alzheimer's disease; Basal forebrain; Deep brain stimulation; Dementia; Nucleus basalis of Meynert; Parkinson's disease dementia

Indexed keywords

ALZHEIMER DISEASE; AROUSAL; ATTENTION; BEHAVIOR; BRAIN DEPTH STIMULATION; COGNITION; COGNITIVE DEFECT; CONTROLLED CLINICAL TRIAL (TOPIC); DEMENTIA; EVIDENCE BASED MEDICINE; HUMAN; MEMORY; MEYNERT BASAL NUCLEUS; MOTOR PERFORMANCE; NERVE CELL NETWORK; NERVE PROJECTION; NEUROANATOMY; NEUROMODULATION; NONHUMAN; PARKINSON DISEASE; PATIENT SELECTION; PERCEPTION; PRIORITY JOURNAL; REVIEW; THERAPY EFFECT;

ALZHEIMER'S DISEASE; BASAL FOREBRAIN; DEEP BRAIN STIMULATION; DEMENTIA; NUCLEUS BASALIS OF MEYNERT; PARKINSON'S DISEASE DEMENTIA;

BASAL NUCLEUS OF MEYNERT; DEEP BRAIN STIMULATION; DEMENTIA; HUMANS;

EID: 84889653958     PISSN: 01497634     EISSN: 18737528     Source Type: Journal    
DOI: 10.1016/j.neubiorev.2013.09.003     Document Type: Review

References (174)

1. Aarsland D., Ballard C., Walker Z., Bostrom F., Alves G., Kossakowski K., Leroi I., Pozo-Rodriguez F., Minthon L., Londos E. Memantine in patients with Parkinson's disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial. Lancet Neurol. 2009, 8:613-618.
2. Aarsland D., Kurz M.W. The epidemiology of dementia associated with Parkinson disease. J. Neurol. Sci. 2010, 289:18-22.
3. Aarsland D., Zaccai J., Brayne C. A systematic review of prevalence studies of dementia in Parkinson's disease. Mov. Disord. 2005, 20:1255-1263.
4. Ackermans L., Duits A., van der Linden C., Tijssen M., Schruers K., Temel Y., Kleijer M., Nederveen P., Bruggeman R., Tromp S., van Kranen-Mastenbroek V., Kingma H., Cath D., Visser-Vandewalle V. Double-blind clinical trial of thalamic stimulation in patients with Tourette syndrome. Brain 2011, 134:832-844.
5. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders 2000, American Psychiatric Association, Washington, DC. Fourth ed., text revision.
6. Ayala G. A hitherto undifferentiated nucleus in the forebrain (nucleus subputaminalis). Brain 1915, 37:433-438.
7. Aucoin J.-S., Jiang P., Aznavour N., Tong X.-K., Buttini M., Descarries L., Hamel E. Selective cholinergic denervation, independent from oxidative stress, in a mouse model of Alzheimer's disease. Neuroscience 2005, 132:73-86.
8. Bakin J.S., Weinberger N.M. Induction of a physiological memory in the cerebral cortex by stimulation of the nucleus basalis. Proc. Natl. Acad. Sci. U.S.A. 1996, 93:11219-11224.
9. Ballard C., Gauthier Serge Corbett A., Brayne C., Aarsland D., Jones E. Alzheimer's disease. Lancet 2011, 377:1019-1031.
10. Barnikol T.T., Pawelczyk N.B.A., Barnikol U.B., Kuhn J., Lenartz D., Sturm V., Tass P.A., Freund H.-J. Changes in apraxia after deep brain stimulation of the nucleus basalis Meynert in a patient with Parkinson dementia syndrome. Mov. Disord. 2010, 25:1519-1520.
11. Bartus R.T., Flicker C., Dean R.L., Pontecorvo M., Figueiredo J.C., Fisher S.K. Selective memory loss following nucleus basalis lesions: long term behavioral recovery despite persistent cholinergic deficiencies. Pharmacol. Biochem. Behav. 1985, 23:125-135.
12. Baskerville K.A., Schweitzer J.B., Herron P. Effects of cholinergic depletion on experience-dependent plasticity in the cortex of the rat. Neuroscience 1997, 80:1159-1169.
13. Bentley P., Driver J., Dolan R.J. Modulation of fusiform cortex activity by cholinesterase inhibition predicts effects on subsequent memory. Brain 2009, 132:2356-2371.
14. Bentley P., Husain M., Dolan R.J. Effects of cholinergic enhancement on visual stimulation, spatial attention and spatial working memory. Neuron 2004, 41:969-982.
15. Bentley P., Driver J., Dolan R.J. Cholinergic modulation of cognition: insights from human pharmacological functional neuroimaging. Prog. Neurobiol. 2011, 94:360-388.
16. Bliss T.V., Collingridge G.L. A synaptic model of memory: long-term potentiation in the hippocampus. Nature 1993, 361:31-39.
17. Blomstedt P., Sjöberg R.L., Hansson M., Bodlund O., Hariz M.I. Deep brain stimulation in the treatment of obsessive-compulsive disorder. World Neurosurg. 2012, 1-9.
18. Boban M., Kostovic I., Simic G. Nucleus subputaminalis: neglected part of the basal nucleus of Meynert. Brain 2006, 129:E42.
19. Bohnen N.I., Kaufer D.I., Hendrickson R., Ivanco L.S., Lopresti B.J., Constantine G.M., Mathis C.A., Davis J.G., Moore R.Y., Dekosky S.T. Cognitive correlates of cortical cholinergic denervation in Parkinson's disease and parkinsonian dementia. J. Neurol. 2006, 253:242-247.
20. Bohnen N.I., Kaufer D.I., Ivanco L.S., Lopresti B., Koeppe R.A., Davis J.G., Mathis C.A., Moore R.Y., DeKosky S.T. Cortical cholinergic function is more severely affected in parkinsonian dementia than in Alzheimer disease: an in vivo positron emission tomographic study. Arch. Neurol. 2003, 60:1745-1748.
21. Boncristiano S., Calhoun M.E., Kelly P.H., Pfeifer M., Bondolfi L., Stalder M., Phinney A.L., Abramowski D., Sturchler-Pierrat C., Enz A., Sommer B., Staufenbiel M., Jucker M. Cholinergic changes in the APP23 transgenic mouse model of cerebral amyloidosis. J. Neurosci. 2002, 22:3234-3243.
22. Bothwell M. Functional interactions of neurotrophins and neurotrophin receptors. Ann. Rev. Neurosci. 1995, 18:223-253.
23. Bouchard R.W. Diagnostic criteria of dementia. Can. J. Neurol. Sci. 2007, 34(Suppl. 1):S11-S18.
24. Bowser R., Kordower J.H., Mufson E.J. A confocal microscopic analysis of galaninergic hyperinnervation of cholinergic basal forebrain neurons in Alzheimer's disease. Brain Pathol. 1997, 7:723-730.
25. Braak H., Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991, 82:239-259.
26. Brookmeyer R., Evans D.A., Hebert L., Langa K.M., Heeringa S.G., Plassman B.L., Kukull W.A. National estimates of the prevalence of Alzheimer's disease in the United States. Alzheimer's Dement. 2011, 7:61-73.
27. Broussard J.I., Karelina K., Sarter M., Givens B. Cholinergic optimization of cue-evoked parietal activity during challenged attentional performance. Eur. J. Neurosci. 2009, 29:1711-1722.
28. Butt A.E., Hodge G.K. Acquisition, retention, and extinction of operant discriminations in rats with nucleus basalis magnocellularis lesions. Behav. Neurosci. 1995, 109:699-713.
29. Buzsáki G., Bickford R.G., Ponomareff G., Thal L.J., Mandel R., Gage F.H. Nucleus basalis and thalamic control of neocortical activity in the freely moving rat. J. Neurosci. 1988, 8:4007-4026.
30. Buzsáki G. Theta oscillations in the hippocampus. Neuron 2002, 33:325-340.
31. Caballol N., Martí M.J., Tolosa E. Cognitive dysfunction and dementia in Parkinson disease. Mov. Disord. 2007, 22(Suppl. 1):S358-S366.
32. Candy J.M., Perry R.H., Perry E.K., Irving D., Blessed G., Fairbairn A.F., Tomlinson B.E. Pathological changes in the nucleus of Meynert in Alzheimer's and Parkinson's diseases. J. Neurol. Sci. 1983, 59:277-289.
33. Chesselet M.-F., Richter F. Modelling of Parkinson's disease in mice. Lancet Neurol. 2011, 10:1108-1118.
34. Choi S.H., Jung T.M., Lee J.E., Lee S.-K., Sohn Y.H., Lee P.H. Volumetric analysis of the substantia innominata in patients with Parkinson's disease according to cognitive status. Neurobiol. Aging 2012, 33:1265-1272.
35. Coleshill S.G., Binnie C.D., Morris R.G., Alarcón G., Van Emde Boas W., Velis D.N., Simmons A., Polkey C.E., Van Veelen C.W.M., Van Rijen P.C. Material-specific recognition memory deficits elicited by unilateral hippocampal electrical stimulation. J. Neurosci. 2004, 24:1612-1616.
36. Counts S.E., Mufson E.J. The role of nerve growth factor receptors in cholinergic basal forebrain degeneration in prodromal Alzheimer disease. J. Neuropathol. Exp. Neurol. 2005, 64:263-272.
37. Croxson P.L., Kyriazis D.A., Baxter M.G. Cholinergic modulation of a specific memory function of prefrontal cortex. Nat. Neurosci. 2011, 14:1510-1512.
38. Deuschl G., Raethjen J., Hellriegel H., Elble R. Treatment of patients with essential tremor. Lancet Neurol. 2011, 10:148-161.
39. Deuschl G., Schade-Brittinger C., Krack P., Volkmann J., Schäfer H., Bötzel K., Daniels C., Deutschländer A., Dillmann U., Eisner W., Gruber D., Hamel W., Herzog J., Hilker R., Klebe S., Kloss M., Koy J., Krause M., Kupsch A., Lorenz D., Lorenzl S., Mehdorn H.M., Moringlane J.R., Oertel W., Pinsker M.O., Reichmann H., Reuss A., Schneider G.-H., Schnitzler A., Steude U., Sturm V., Timmermann L., Tronnier V., Trottenberg T., Wojtecki L., Wolf E., Poewe W., Voges J. A randomized trial of deep-brain stimulation for Parkinson's disease. N. Engl. J. Med. 2006, 355:896-908.
40. Divac I. Magnocellular nuclei of the basal forebrain project to neocortex, brain stem, and olfactory bulb. Review of some functional correlates. Brain Res. 1975, 93:385-398.
41. Dubois B., Feldman H.H., Jacova C., Dekosky S.T., Barberger-Gateau P., Cummings J., Delacourte A., Galasko D., Gauthier S., Jicha G., Meguro K., O'brien J., Pasquier F., Robert P., Rossor M., Salloway S., Stern Y., Visser P.J., Scheltens P. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol. 2007, 6:734-746.
42. Dunne M.P., Hartley L.R. The effects of scopolamine upon verbal memory: evidence for an attentional hypothesis. Acta Psychol. 1985, 58:205-217.
43. Emre M., Aarsland D., Albanese A., Byrne E.J., Deuschl G., De Deyn P.P., Durif F., Kulisevsky J., Van Laar T., Lees A., Poewe W., Robillard A., Rosa M.M., Wolters E., Quarg P., Tekin S., Lane R. Rivastigmine for dementia associated with Parkinson's disease. N. Engl. J. Med. 2004, 351:2509-2518.
44. Emre M., Aarsland D., Brown R., Burn D.J., Duyckaerts C., Mizuno Y., Broe G.A., Cummings J., Dickson D.W., Gauthier S., Goldman J., Goetz C., Korczyn A., Lees A., Levy R., Litvan I., McKeith I., Olanow W., Poewe W., Quinn N., Sampaio C., Tolosa E., Dubois B. Clinical diagnostic criteria for dementia associated with Parkinson's disease. Mov. Disord. 2007, 22:1689-1707.
45. Emre M., Tsolaki M., Bonuccelli U., Destée A., Tolosa E., Kutzelnigg A., Ceballos-Baumann A., Zdravkovic S., Bladström A., Jones R. Memantine for patients with Parkinson's disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2010, 9:969-977.
46. Eriksdotter-Jönhagen M., Linderoth B., Lind G., Aladellie L., Almkvist O., Andreasen N., Blennow K., Bogdanovic N., Jelic V., Kadir A., Nordberg A., Sundström E., Wahlund L.-O., Wall A., Wiberg M., Winblad B., Seiger A., Almqvist P., Wahlberg L. Encapsulated cell biodelivery of nerve growth factor to the Basal forebrain in patients with Alzheimer's disease. Dement. Geriatr. Cogn. Disord. 2012, 33:18-28.
47. Etienne P., Robitaille Y., Wood P., Gauthier S., Nair N.P., Quirion R. Nucleus basalis neuronal loss, neuritic plaques and choline acetyltransferase activity in advanced Alzheimer's disease. Neuroscience 1986, 19:1279-1291.
48. Ferri C.P., Prince M., Brayne C., Brodaty H., Fratiglioni L., Ganguli M., Hall K., Hasegawa K., Hendrie H., Huang Y., Jorm A., Mathers C., Menezes P.R., Rimmer E., Scazufca M. Global prevalence of dementia: a Delphi consensus study. Lancet 2005, 366:2112-2117.
49. Fisher A., Brandeis R., Chapman S., Pittel Z., Michaelson D.M. M1 muscarinic agonist treatment reverses cognitive and cholinergic impairments of apolipoprotein E-deficient mice. J. Neurochem. 1998, 70:1991-1997.
50. Foltynie T., Hariz M.I. Surgical management of Parkinson's disease. Expert Rev. Neurother. 2010, 10:903-914.
51. Foltynie T., Zrinzo L., Martinez-Torres I., Tripoliti E., Petersen E., Holl E., Aviles-Olmos I., Jahanshahi M., Hariz M., Limousin P. MRI-guided STN DBS in Parkinson's disease without microelectrode recording: efficacy and safety. J. Neurol. Neurosurg. Psychiatry 2011, 82:358-363.
52. Freund H.-J., Kuhn J., Lenartz D., Mai J.K., Schnell T., Klosterkoetter J., Sturm V. Cognitive functions in a patient with Parkinson-dementia syndrome undergoing deep brain stimulation. Arch. Neurol. 2009, 66:781-785.
53. Fuller P.M., Fuller P., Sherman D., Pedersen N.P., Saper C.B., Lu J. Reassessment of the structural basis of the ascending arousal system. J. Comp. Neurol. 2011, 519:933-956.
54. Gaspar P., Berger B., Alvarez C., Vigny A., Henry J.P. Catecholaminergic innervation of the septal area in man: immunocytochemical study using TH and DBH antibodies. J. Comp. Neurol. 1985, 241:12-33.
55. Gaspar P., Gray F. Dementia in idiopathic Parkinson's disease. A neuropathological study of 32 cases. Acta. Neuropathol. 1984, 64:43-52.
56. Geula C., Bu J., Nagykery N., Scinto L.F.M., Chan J., Joseph J., Parker R., Wu C.-K. Loss of calbindin-D28k from aging human cholinergic basal forebrain: relation to neuronal loss. J. Comp. Neurol. 2003, 455:249-259.
57. Gilmor M.L., Erickson J.D., Varoqui H., Hersh L.B., Bennett D.A., Cochran E.J., Mufson E.J., Levey A.I. Preservation of nucleus basalis neurons containing choline acetyltransferase and the vesicular acetylcholine transporter in the elderly with mild cognitive impairment and early Alzheimer's disease. J. Comp. Neurol. 1999, 411:693-704.
58. Givens B. Stimulus-evoked resetting of the dentate theta rhythm: relation to working memory. Neuroreport 1996, 8:159-163.
59. Goard M., Dan Y. Basal forebrain activation enhances cortical coding of natural scenes. Nat. Neurosci. 2009, 12:1444-1449.
60. Gorry J.D. Studies on the comparative anatomy of the ganglion basale of Meynert. Acta Anat. 1963, 55:51-104.
61. Grill W.M., Snyder A.N., Miocinovic S. Deep brain stimulation creates an informational lesion of the stimulated nucleus. Neuroreport 2004, 15:1137-1140.
62. Gritti I., Mainville L., Jones B.E. Codistribution of GABA- with acetylcholine-synthesizing neurons in the basal forebrain of the rat. J. Comp. Neurol. 1993, 329:438-457.
63. Grothe M., Heinsen H., Teipel S.J. Atrophy of the cholinergic Basal forebrain over the adult age range and in early stages of Alzheimer's disease. Biol. Psychiatry 2012, 71:805-813.
64. Grothe M., Zaborszky L., Atienza M., Gil-Neciga E., Rodriguez-Romero R., Teipel S.J., Amunts K., Suarez-Gonzalez A., Cantero J.L. Reduction of basal forebrain cholinergic system parallels cognitive impairment in patients at high risk of developing Alzheimer's disease. Cereb. Cortex 2010, 20:1685-1695.
65. Hamani C., McAndrews M.P., Cohn M., Oh M., Zumsteg D., Shapiro C.M., Wennberg R.A., Lozano A.M. Memory enhancement induced by hypothalamic/fornix deep brain stimulation. Ann. Neurol. 2008, 63:119-123.
66. Hanyu H., Asano T., Sakurai H., Tanaka Y., Takasaki M., Abe K. MR analysis of the substantia innominata in normal aging, Alzheimer disease, and other types of dementia. Am. J. Neuroradiol. 2002, 23:27-32.
67. Hasselmo M.E., McGaughy J. High acetylcholine levels set circuit dynamics for attention and encoding and low acetylcholine levels set dynamics for consolidation. Prog. Brain Res. 2004, 145:207-231.
68. Hasselmo M.E., Sarter M. Modes and models of forebrain cholinergic neuromodulation of cognition. Neuropsychopharmacology 2011, 36:52-73.
69. Hefti F. Nerve growth factor promotes survival of septal cholinergic neurons after fimbrial transections. J. Neurosci. 1986, 6:2155-2162.
70. Hernandez D., Sugaya K., Qu T., McGowan E., Duff K., McKinney M. Survival and plasticity of basal forebrain cholinergic systems in mice transgenic for presenilin-1 and amyloid precursor protein mutant genes. Neuroreport 2001, 12:1377-1384.
71. Herrero J.L., Roberts M.J., Delicato L.S., Gieselmann M.A., Dayan P., Thiele A. Acetylcholine contributes through muscarinic receptors to attentional modulation in V1. Nature 2008, 454:1110-1114.
72. Hong J.H., Jang S.H. Neural pathway from nucleus basalis of Meynert passing through the cingulum in the human brain. Brain Res. 2010, 1346:190-194.
73. Huerta P.T., Lisman J.E. Heightened synaptic plasticity of hippocampal CA1 neurons during a cholinergically induced rhythmic state. Nature 1993, 364:723-725.
74. Ihl R., Frölich L., Winblad B., Schneider L., Burns A., Möller H.-J. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of Alzheimer's disease and other dementias. World J. Biol. Psychiatry 2011, 12:2-32.
75. Ikonomovic M.D., Nocera R., Mizukami K., Armstrong D.M. Age-related loss of the AMPA receptor subunits GluR2/3 in the human nucleus basalis of Meynert. Exp. Neurol. 2000, 166:363-375.
76. Irle E., Markowitsch H.J. Basal forebrain-lesioned monkeys are severely impaired in tasks of association and recognition memory. Ann. Neurol. 1987, 22:735-743.
77. Jack C.R., Knopman D.S., Jagust W.J., Petersen R.C., Weiner M.W., Aisen P.S., Shaw L.M., Vemuri P., Wiste H.J., Weigand S.D., Lesnick T.G., Pankratz V.S., Donohue M.C., Trojanowski J.Q. Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol. 2013, 12:207-216.
78. Jaffar S., Counts S.E., Ma S.Y., Dadko E., Gordon M.N., Morgan D., Mufson E.J. Neuropathology of mice carrying mutant APP(swe) and/or PS1(M146L) transgenes: alterations in the p75(NTR) cholinergic basal forebrain septohippocampal pathway. Exp. Neurol. 2001, 170:227-243.
79. Jenkinson N., Nandi D., Miall R.C., Stein J.F., Aziz T.Z. Pedunculopontine nucleus stimulation improves akinesia in a Parkinsonian monkey. Neuroreport 2004, 15:2621-2624.
80. Jones B.E. Modulation of cortical activation and behavioral arousal by cholinergic and orexinergic systems. Ann. N. Y. Acad. Sci. 2008, 1129:26-34.
81. Jones B.E., Cuello A.C. Afferents to the basal forebrain cholinergic cell area from pontomesencephalic-catecholamine, serotonin, and acetylcholine-neurons. Neuroscience 1989, 31:37-61.
82. Jones E.G., Burton H., Saper C.B., Swanson L.W. Midbrain, diencephalic and cortical relationships of the basal nucleus of Meynert and associated structures in primates. J. Comp. Neurol. 1976, 167:385-419.
83. Kalmbach A., Hedrick T., Waters J. Selective optogenetic stimulation of cholinergic axons in neocortex. J. Neurophysiol. 2012, 107:2008-2019.
84. Karran E. Current status of vaccination therapies in Alzheimer's disease. J. Neurochem. 2012, 123:647-651.
85. Kilgard M.P., Merzenich M.M. Cortical map reorganization enabled by nucleus basalis activity. Science 1998, 279:1714-1718.
86. Kodama S. Pathologisch-anatomische Untersuchungen mit Bezug auf die sorgenannten Basalganglien und ihre Adnexe Neurologische und Psychiatrische Abhandlungen aus dem Schweizer. Archiv fur Neurologie und Psychiatrie 1929, 8:1-206.
87. Kölliker A. Handbuch der Gewebelehre des Menschen. Vol. 2. Nervensystem 1896, Engelmann, Leipzig.
88. Krack P., Batir A., Van Blercom N., Chabardes S., Fraix V., Ardouin C., Koudsie A., Limousin P.D., Benazzouz A., LeBas J.F., Benabid A.-L., Pollak P. Five-year follow-up of bilateral stimulation of the subthalamic nucleus in advanced Parkinson's disease. N. Engl. J. Med. 2003, 349:1925-1934.
89. Kurosawa M., Sato A., Sato Y. Stimulation of the nucleus basalis of Meynert increases acetylcholine release in the cerebral cortex in rats. Neurosci. Lett. 1989, 98:45-50.
90. Lacruz M.E., Valentín A., Seoane J.J.G., Morris R.G., Selway R.P., Alarcón G. Single pulse electrical stimulation of the hippocampus is sufficient to impair human episodic memory. Neuroscience 2010, 170:623-632.
91. Laursen B., Mørk A., Plath N., Kristiansen U., Bastlund J.F. Cholinergic degeneration is associated with increased plaque deposition and cognitive impairment in APPswe/PS1dE9 mice. Behav. Brain Res. 2013, 240:146-152.
92. Laxton A.W., Lozano A.M. Deep brain stimulation for the treatment of Alzheimer disease and dementias. World Neurosurg. 2012, 1-8.
93. Laxton A.W., Tang-Wai D.F., McAndrews M.P., Zumsteg D., Wennberg R., Keren R., Wherrett J., Naglie G., Hamani C., Smith G.S., Lozano A.M. A phase I trial of deep brain stimulation of memory circuits in Alzheimer's disease. Ann. Neurol. 2010, 68:521-534.
94. Leanza G., Muir J., Nilsson O.G., Wiley R.G., Dunnett S.B., Bjorklund A. Selective immunolesioning of the basal forebrain cholinergic system disrupts short-term memory in rats. Eur. J. Neurosci. 1996, 8:1535-1544.
95. Lee D.J., Gurkoff G.G., Izadi A., Berman R.F., Ekstrom A.D., Muizelaar J.P., Lyeth B.G., Shahlaie K. Medial septal nucleus theta frequency deep brain stimulation improves spatial working memory after traumatic brain injury. J. Neurotrauma 2013, 30:131-139.
96. Lee D.J., Gurkoff G.G., Izadi A., Ekstrom A.D., Muizelaar J.M., Lyeth B.G., Shahlaie K. Deep brain stimulation of the medial septal nucleus improves spatial working memory following pilocarpine-induced status epilepticus. Neurosurgery 2013, 60(Suppl. 1):164.
97. Lee J.E., Cho K.H., Song S.K., Kim H.J., Lee H.S., Sohn Y.H., Lee P.H. Exploratory analysis of neuropsychological and neuroanatomical correlates of progressive mild cognitive impairment in Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 2013, (July 4, Epub ahead of print).
98. Lee M.G., Hassani O.K., Alonso A., Jones B.E. Cholinergic basal forebrain neurons burst with theta during waking and paradoxical sleep. J. Neurosci. 2005, 25:4365-4369.
99. Limousin P., Krack P., Pollak P., Benazzouz A., Ardouin C., Hoffmann D., Benabid A.L. Electrical stimulation of the subthalamic nucleus in advanced Parkinson's disease. N. Engl. J. Med. 1998, 339:1105-1111.
100. Llibre Rodriguez J.J., Ferri C.P., Acosta D., Guerra M., Huang Y., Jacob K.S., Krishnamoorthy E.S., Salas A., Sosa A.L., Acosta I., Dewey M.E., Gaona C., Jotheeswaran A.T., Li S., Rodriguez D., Rodriguez G., Kumar P.S., Valhuerdi A., Prince M. Prevalence of dementia in Latin America, India, and China: a population-based cross-sectional survey. Lancet 2008, 372:464-474.
101. Lozano A.M., Giacobbe P., Hamani C., Rizvi S.J., Kennedy S.H., Kolivakis T.T., Debonnel G., Sadikot A.F., Lam R.W., Howard A.K., Ilcewicz-Klimek M., Honey C.R., Mayberg H.S. A multicenter pilot study of subcallosal cingulate area deep brain stimulation for treatment-resistant depression. J. Neurosurg. 2012, 116:315-322.
102. Magen I., Fleming S.M., Zhu C., Garcia E.C., Cardiff K.M., Dinh D., De La Rosa K., Sanchez M., Torres E.R., Masliah E., Jentsch J.D., Chesselet M.-F. Cognitive deficits in a mouse model of pre-manifest Parkinson's disease. Eur. J. Neurosci. 2012, 35:870-882.
103. Maloney K.J., Cape E.G., Gotman J., Jones B.E. High-frequency gamma electroencephalogram activity in association with sleep-wake states and spontaneous behaviors in the rat. Neuroscience 1997, 76:541-555.
104. Mandel R.J., Gage F.H., Thal L.J. Spatial learning in rats: correlation with cortical choline acetyltransferase and improvement with NGF following NBM damage. Exp. Neurol. 1989, 104:208-217.
105. Martínez-Fernández R., Zrinzo L., Aviles-Olmos I., Hariz M., Martinez-Torres I., Joyce E., Jahanshahi M., Limousin P., Foltynie T. Deep brain stimulation for Gilles de la Tourette syndrome: a case series targeting subregions of the globus pallidus internus. Mov. Disord. 2011, 26:1922-1930.
106. McCartney H., Johnson A.D., Weil Z.M., Givens B. Theta reset produces optimal conditions for long-term potentiation. Hippocampus 2004, 14:684-687.
107. McConnell G.C., So R.Q., Hilliard J.D., Lopomo P., Grill W.M. Effective deep brain stimulation suppresses low-frequency network oscillations in the basal ganglia by regularizing neural firing patterns. J. Neurosci. 2012, 32:15657-15668.
108. McGaugh J.L. Memory consolidation and the amygdala: a systems perspective. Trends Neurosci. 2002, 25:456.
109. McGaughy J., Dalley J.W., Morrison C.H., Everitt B.J., Robbins T.W. Selective behavioral and neurochemical effects of cholinergic lesions produced by intrabasalis infusions of 192 IgG-saporin on attentional performance in a five-choice serial reaction time task. J. Neurosci. 2002, 22:1905-1913.
110. McIntyre C.C., Grill W.M., Sherman D.L., Thakor N.V. Cellular effects of deep brain stimulation: model-based analysis of activation and inhibition. J. Neurophysiol. 2004, 91:1457-1469.
111. McIntyre C.C., Hahn P.J. Network perspectives on the mechanisms of deep brain stimulation. Neurobiol. Dis. 2010, 38:329-337.
112. McKhann G.M., Knopman D.S., Chertkow H., Hyman B.T., Jack C.R., Kawas C.H., Klunk W.E., Koroshetz W.J., Manly J.J., Mayeux R., Mohs R.C., Morris J.C., Rossor M.N., Scheltens P., Carrillo M.C., Thies B., Weintraub S., Phelps C.H. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer's Dement. 2011, 7:263-269.
113. McLin D.E., Miasnikov A.A., Weinberger N.M. Induction of behavioral associative memory by stimulation of the nucleus basalis. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:4002-4007.
114. Mesulam M.M. Asymmetry of neural feedback in the organization of behavioral states. Science 1987, 237:537-538.
115. Mesulam M.M., Geula C. Nucleus basalis (Ch4) and cortical cholinergic innervation in the human brain: observations based on the distribution of acetylcholinesterase and choline acetyltransferase. J. Comp. Neurol. 1988, 275:216-240.
116. Mesulam M.M., Mash D., Hersh L., Bothwell M., Geula C. Cholinergic innervation of the human striatum, globus pallidus, subthalamic nucleus, substantia nigra, and red nucleus. J. Comp. Neurol. 1992, 323:252-268.
117. Mesulam M.M., Mufson E.J. Neural inputs into the nucleus basalis of the substantia innominata (Ch4) in the rhesus monkey. Brain 1984, 107(Pt 1):253-274.
118. Mesulam M.M., Mufson E.J., Levey A.I., Wainer B.H. Cholinergic innervation of cortex by the basal forebrain: cytochemistry and cortical connections of the septal area, diagonal band nuclei, nucleus basalis (substantia innominata), and hypothalamus in the rhesus monkey. J. Comp. Neurol. 1983, 214:170-197.
119. Metherate R., Cox C.L., Ashe J.H. Cellular bases of neocortical activation: modulation of neural oscillations by the nucleus basalis and endogenous acetylcholine. J. Neurosci. 1992, 12:4701-4711.
120. Meynert T. The brain of mammals. A Manual of Histology 1872, 650-766. (J.J. Putnam, Trans.), William Wood, New York. S. Stricker (Ed.).
121. Miasnikov A.A., Chen J.C., Weinberger N.M. Behavioral memory induced by stimulation of the nucleus basalis: effects of contingency reversal. Neurobiol. Learn. Mem. 2009, 91:298-309.
122. Montero-Pastor A., Vale-Martínez A., Guillazo-Blanch G., Nadal-Alemany R., Martí-Nicolovius M., Morgado-Bernal I. Nucleus basalis magnocellularis electrical stimulation facilitates two-way active avoidance retention, in rats. Brain Res. 2001, 900:337-341.
123. Montero-Pastor A., Vale-Martínez A., Guillazo-Blanch G., Martí-Nicolovius M. Effects of electrical stimulation of the nucleus basalis on two-way active avoidance acquisition, retention, and retrieval. Behav. Brain Res. 2004, 154:41-54.
124. Moruzzi G., Magoun H.W. Brainstem reticular formation and activation of the EEG. Electroencephalogr. Clin. Neurophysiol. 1949, 1:455-473.
125. Mufson E.J., Jaffar S., Levey A.I. m2 muscarinic acetylcholine receptor-immunoreactive neurons are not reduced within the nucleus basalis in Alzheimer's disease: relationship with cholinergic and galaninergic perikarya. J. Comp. Neurol. 1998, 392:313-329.
126. Mufson E.J., Kroin J.S., Sendera T.J., Sobreviela T. Distribution and retrograde transport of trophic factors in the central nervous system: functional implications for the treatment of neurodegenerative diseases. Prog. Neurobiol. 1999, 57:451-484.
127. Mufson E.J., Ginsberg S.D., Ikonomovic M.D., DeKosky S.T. Human cholinergic basal forebrain: chemoanatomy and neurologic dysfunction. J. Chem. Neuroanat. 2003, 26:233-242.
128. Muir J.L., Dunnett S.B., Robbins T.W., Everitt B.J. Attentional functions of the forebrain cholinergic systems: effects of intraventricular hemicholinium, physostigmine, basal forebrain lesions and intracortical grafts on a multiple-choice serial reaction time task. Exp. Brain Res. 1992, 89:611-622.
129. Murray C.L., Fibiger H.C. Learning and memory deficits after lesions of the nucleus basalis magnocellularis: reversal by physostigmine. Neuroscience 1985, 14:1025-1032.
130. Nagai T., Kimura H., Maeda T., McGeer P.L., Peng F., McGeer E.G. Cholinergic projections from the basal forebrain of rat to the amygdala. J. Neurosci. 1982, 2:513-520.
131. Nandi D., Jenkinson N., Stein J., Aziz T. The pedunculopontine nucleus in Parkinson's disease: primate studies. Br. J. Neurosurg. 2008, 22(Suppl. 1):S4-S8.
132. Nuber S., Petrasch-Parwez E., Winner B., Winkler J., von Hörsten S., Schmidt T., Boy J., Kuhn M., Nguyen H.P., Teismann P., Schulz J.B., Neumann M., Pichler B.J., Reischl G., Holzmann C., Schmitt I., Bornemann A., Kuhn W., Zimmermann F., Servadio A., Riess O. Neurodegeneration and motor dysfunction in a conditional model of Parkinson's disease. J. Neurosci. 2008, 28:2471-2484.
133. Olesen J., Gustavsson A., Svensson M., Wittchen H.-U., Jönsson B. The economic cost of brain disorders in Europe. Eur. J. Neurol. 2012, 19:155-162.
134. Pagonabarraga J., Kulisevsky J. Cognitive impairment and dementia in Parkinson's disease. Neurobiol. Dis. 2012, 46:590-596.
135. Perez S.E., He B., Muhammad N., Oh K.-J., Fahnestock M., Ikonomovic M.D., Mufson E.J. Cholinotrophic basal forebrain system alterations in 3xTg-AD transgenic mice. Neurobiol. Dis. 2011, 41:338-352.
136. Perry E.K., Curtis M., Dick D.J., Candy J.M., Atack J.R., Bloxham C.A., Blessed G., Fairbairn A., Tomlinson B.E., Perry R.H. Cholinergic correlates of cognitive impairment in Parkinson's disease: comparisons with Alzheimer's disease. J. Neurol. Neurosurg. Psychiatry 1985, 48:413-421.
137. Petersen R.C., Arsenal E., Ground A.P. Scopolamine induced learning failures in man. Psychopharmacology (Berl.) 1977, 289:283-289.
138. Qaseem A., Snow V., Cross J.T., Forciea M.A., Hopkins R., Shekelle P., Adelman A., Mehr D., Schellhase K., Campos-Outcalt D., Santaguida P., Owens D.K. Current pharmacologic treatment of dementia: a clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians. Ann. Intern. Med. 2008, 148:370-378.
139. Raghavachari S., Kahana M.J., Rizzuto D.S., Caplan J.B., Kirschen M.P., Bourgeois B., Madsen J.R., Lisman J.E. Gating of human theta oscillations by a working memory task. J. Neurosci. 2001, 21:3175-3183.
140. Ramón-Moliner E., Nauta W.J. The isodendritic core of the brain stem. J. Comp. Neurol. 1966, 126:311-335.
141. Reid W.G., Hely M.A., Morris J.G., Broe G.A., Adena M., Sullivan D.J., Williamson P.M. A longitudinal of Parkinson's disease: clinical and neuropsychological correlates of dementia. J. Clin. Neurosci. 1996, 3:327-333.
142. Rein M.L., Deussing J.M. The optogenetic (r)evolution. Mol. Genet. Genomics 2012, 287:95-109.
143. Reitz C., Brayne C., Mayeux R. Epidemiology of Alzheimer disease. Nat. Rev. Neurol. 2011, 7:137-152.
144. Robbins T.W., Everitt B.J., Marston H.M., Wilkinson J., Jones G.H., Page K.J. Comparative effects of ibotenic acid- and quisqualic acid-induced lesions of the substantia innominata on attentional function in the rat: further implications for the role of the cholinergic neurons of the nucleus basalis in cognitive processes. Behav. Brain Res. 1989, 35:221-240.
145. Roberts A.C., Robbins T.W., Everitt B.J., Muir J.L. A specific form of cognitive rigidity following excitotoxic lesions of the basal forebrain in marmosets. Neuroscience 1992, 47:251-264.
146. Roberts M.J., Zinke W., Guo K., Robertson R., McDonald J.S., Thiele A. Acetylcholine dynamically controls spatial integration in marmoset primary visual cortex. J. Neurophysiol. 2005, 93:2062-2072.
147. Rosin B., Slovik M., Mitelman R., Rivlin-Etzion M., Haber S.N., Israel Z., Vaadia E., Bergman H. Closed-loop deep brain stimulation is superior in ameliorating parkinsonism. Neuron 2011, 72:370-384.
148. Rossor M.N., Svendsen C., Hunt S.P., Mountjoy C.Q., Roth M., Iversen L.L. The substantia innominata in Alzheimer's disease: an histochemical and biochemical study of cholinergic marker enzymes. Neurosci. Lett. 1982, 28:217-222.
149. Russchen F.T., Amaral D.G., Price J.L. The afferent connections of the substantia innominata in the monkey, Macaca fascicularis. J. Comp. Neurol. 1985, 242:1-27.
150. Saper C.B., Scammell T.E., Lu J. Hypothalamic regulation of sleep and circadian rhythms. Nature 2005, 437:1257-1263.
151. Sarter M., Bruno J.P., Givens B. Attentional functions of cortical cholinergic inputs: what does it mean for learning and memory?. Neurobiol. Learn. Mem. 2003, 80:245-256.
152. Sarter M., Gehring W.J., Kozak R. More attention must be paid: the neurobiology of attentional effort. Brain Res. Rev. 2006, 51:145-160.
153. Selden N.R., Gitelman D.R., Salamon-Murayama N., Parrish T.B., Mesulam M.M. Trajectories of cholinergic pathways within the cerebral hemispheres of the human brain. Brain 1998, 121(Pt 1):2249-2257.
154. Shimada H., Hirano S., Shinotoh H., Aotsuka A., Sato K., Tanaka N., Ota T., Asahina M., Fukushi K., Kuwabara S., Hattori T., Suhara T., Irie T. Mapping of brain acetylcholinesterase alterations in Lewy body disease by PET. Neurology 2009, 73:273-278.
155. Simić G., Mrzljak L., Fucić A., Winblad B., Lovrić H., Kostović I. Nucleus subputaminalis (Ayala): the still disregarded magnocellular component of the basal forebrain may be human specific and connected with the cortical speech area. Neuroscience 1999, 89:73-89.
156. Sobreviela T., Clary D.O., Reichardt L.F., Brandabur M.M., Kordower J.H., Mufson E.J. TrkA-immunoreactive profiles in the central nervous system: colocalization with neurons containing p75 nerve growth factor receptor, choline acetyltransferase, and serotonin. J. Comp. Neurol. 1994, 350:587-611.
157. Suthana N., Haneef Z., Stern J., Mukamel R., Behnke E., Knowlton B., Fried I. Memory enhancement and deep-brain stimulation of the entorhinal area. N. Engl. J. Med. 2012, 366:502-510.
158. Teipel S.J., Flatz W.H., Heinsen H., Bokde A.L.W., Schoenberg S.O., Stöckel S., Dietrich O., Reiser M.F., Möller H.-J., Hampel H. Measurement of basal forebrain atrophy in Alzheimer's disease using MRI. Brain 2005, 128:2626-2644.
159. Teipel S.J., Meindl T., Grinberg L., Grothe M., Cantero J.L., Reiser M.F., Möller H.-J., Heinsen H., Hampel H. The cholinergic system in mild cognitive impairment and Alzheimer's disease: an in vivo MRI and DTI study. Hum. Brain Mapp. 2011, 32:1349-1362.
160. Thies W., Bleiler L. 2011 Alzheimer's disease facts and figures. Alzheimer's Dement. 2011, 7:208-244.
161. Turnbull I.M., McGeer P.L., Beattie L., Calne D., Pate B. Stimulation of the basal nucleus of Meynert in senile dementia of Alzheimer's type. A preliminary report. Appl. Neurophysiol. 1985, 48:216-221.
162. Vertes R.P. Hippocampal theta rhythm: a tag for short-term memory. Hippocampus 2005, 15:923-935.
163. Vidailhet M., Jutras M.-F., Grabli D., Roze E. Deep brain stimulation for dystonia. J. Neurol. Neurosurg. Psychiatry 2012, 1-14.
164. Voytko M.L. Cognitive functions of the basal forebrain cholinergic system in monkeys: memory or attention?. Behav. Brain Res. 1996, 75:13-25.
165. Voytko M.L., Olton D.S., Richardson R.T., Gorman L.K., Tobin J.R., Price D.L. Basal forebrain lesions in monkeys disrupt attention but not learning and memory. J. Neurosci. 1994, 14:167-186.
166. Wainer B.H., Mesulam M.M. Ascending cholinergic pathways in the rat brain. Brain Cholinergic Systems 1990, 65-119. Oxford University Press, Oxford. M. Steriade, D. Biesold (Eds.).
167. Wahlberg L.U., Lind G., Almqvist P.M., Kusk P., Tornøe J., Juliusson B., Söderman M., Selldén E., Seiger Å., Eriksdotter-Jönhagen M., Linderoth B. Targeted delivery of nerve growth factor via encapsulated cell biodelivery in Alzheimer disease: a technology platform for restorative neurosurgery. J. Neurosurg. 2012, 117:340-347.
168. Webster H.H., Hanisch U.K., Dykes R.W., Biesold D. Basal forebrain lesions with or without reserpine injection inhibit cortical reorganization in rat hindpaw primary somatosensory cortex following sciatic nerve section. Somatosens. Mot. Res. 1991, 8:327-346.
169. Whitehouse P.J., Hedreen J.C., White C.L., Price D.L. Basal forebrain neurons in the dementia of Parkinson disease. Ann. Neurol. 1983, 13:243-248.
170. Whitehouse P.J., Price D.L., Clark A.W., Coyle J.T., DeLong M.R. Alzheimer disease: evidence for selective loss of cholinergic neurons in the nucleus basalis. Ann. Neurol. 1981, 10:122-126.
171. Williams A., Gill S., Varma T., Jenkinson C., Quinn N., Mitchell R., Scott R., Ives N., Rick C., Daniels J., Patel S., Wheatley K. Deep brain stimulation plus best medical therapy versus best medical therapy alone for advanced Parkinson's disease (PD SURG trial): a randomised open-label trial. Lancet Neurol. 2010, 9:581-591.
172. Williams J.M., Givens B. Stimulation-induced reset of hippocampal theta in the freely performing rat. Hippocampus 2003, 13:109-116.
173. Wimo A., Jönsson L., Gustavsson A., McDaid D., Ersek K., Georges J., Gulácsi L., Karpati K., Kenigsberg P., Valtonen H. The economic impact of dementia in Europe in 2008-cost estimates from the Eurocode project. Int. J. Geriatr. Psychiatry 2011, 26:825-832.
174. Wu D.-C., Zhu-Ge Z.-B., Yu C.-Y., Fang Q., Wang S., Jin C.-L., Zhang S.-H., Chen Z. Low-frequency stimulation of the tuberomammillary nucleus facilitates electrical amygdaloid-kindling acquisition in Sprague-Dawley rats. Neurobiol. Dis. 2008, 32:151-156.